{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:22:57Z","timestamp":1767612177398,"version":"3.45.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10557-024-07609-6","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T14:03:44Z","timestamp":1722348224000},"page":"1075-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Study-level Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-9850","authenticated-orcid":false,"given":"Bing","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"25","key":"7609_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/CIR.0000000000000134","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):344\u2013426. https:\/\/doi.org\/10.1161\/CIR.0000000000000134","journal-title":"Circulation"},{"key":"7609_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"7609_CR3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.jacc.2011.07.021","volume":"58","author":"JW Suh","year":"2011","unstructured":"Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011;58:1750\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2011.07.021","journal-title":"J Am Coll Cardiol"},{"key":"7609_CR4","doi-asserted-by":"publisher","unstructured":"Lindsey JB, Marso SP, Pencina M, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv. 2009;2(11):1074\u201382. https:\/\/doi.org\/10.1016\/j.jcin.2009.09.002","DOI":"10.1016\/j.jcin.2009.09.002"},{"key":"7609_CR5","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853\u201363. https:\/\/doi.org\/10.1001\/jama.289.7.853","DOI":"10.1001\/jama.289.7.853"},{"key":"7609_CR6","doi-asserted-by":"publisher","unstructured":"Montalescot G, Zeymer U, Silvain J, et al; ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378: 693\u2013703. https:\/\/doi.org\/10.1016\/S0140-6736(11)60876-3","DOI":"10.1016\/S0140-6736(11)60876-3"},{"issue":"21","key":"7609_CR7","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008May 22;358(21):2218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa0708191","journal-title":"N Engl J Med"},{"key":"7609_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384:1849\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(14)60924-7","journal-title":"Lancet"},{"key":"7609_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacc.2018.12.023","volume":"73","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Carrara G, Frigoli E, et al. post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome. J Am Coll Cardiol. 2019;73:758\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.023","journal-title":"J Am Coll Cardiol"},{"key":"7609_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ccd.26859","volume":"90","author":"R Shah","year":"2017","unstructured":"Shah R, Matin K, Rogers KC, Rao SV. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: a comprehensive pairwise and network meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2017;90:196\u2013204. https:\/\/doi.org\/10.1002\/ccd.26859","journal-title":"Catheter Cardiovasc Interv"},{"issue":"16","key":"7609_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","volume":"148","author":"B Bikdeli","year":"2023","unstructured":"Bikdeli B, Erlinge D, Valgimigli M, et al. Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials. Circulation. 2023;148(16):1207\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063946","journal-title":"Circulation"},{"key":"7609_CR12","doi-asserted-by":"publisher","unstructured":"Han Y, Guo J, Zheng Y, et al. BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;13(13):1336\u201346. https:\/\/doi.org\/10.1001\/jama.2015.2323","DOI":"10.1001\/jama.2015.2323"},{"issue":"12","key":"7609_CR13","doi-asserted-by":"publisher","first-page":"008969","DOI":"10.1161\/CIRCINTERVENTIONS.120.008969","volume":"14","author":"S James","year":"2021","unstructured":"James S, Koul S, Andersson J, et al. Bivalirudin versus heparin monotherapy in ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2021;14(12):008969. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.120.008969","journal-title":"Circ Cardiovasc Interv"},{"key":"7609_CR14","doi-asserted-by":"publisher","first-page":"107602962210779","DOI":"10.1177\/10760296221077973","volume":"28","author":"ZD Wang","year":"2022","unstructured":"Wang ZD, Chen YX, Liu M, et al. Safety of Bivalirudin combined with Ticagrelor in the emergency PCI in patients with acute ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost. 2022;28:10760296221077972. https:\/\/doi.org\/10.1177\/10760296221077973","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10366","key":"7609_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized trial. Lancet. 2022;400(10366):1847\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(22)01999-7","journal-title":"Lancet"},{"key":"7609_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.31222\/osf.io\/v7gm2","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol. 2021;74:790\u20139. https:\/\/doi.org\/10.31222\/osf.io\/v7gm2","journal-title":"Rev Esp Cardiol"},{"key":"7609_CR17","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Assessing the risk of bias in the included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. London: the cochrane collaboration. 2011."},{"key":"7609_CR18","doi-asserted-by":"publisher","unstructured":"Steg PG, van 't Hof A, Hamm CW, et al. EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1311096","DOI":"10.1056\/NEJMoa1311096"},{"issue":"10","key":"7609_CR19","doi-asserted-by":"publisher","first-page":"e0259148","DOI":"10.1371\/journal.pone.0259148","volume":"16","author":"A Faour","year":"2021","unstructured":"Faour A, Collins N, Williams T, et al. Reperfusion After Fibrinolytic Therapy (RAFT): an open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention. PLoS ONE. 2021;16(10):e0259148. https:\/\/doi.org\/10.1371\/journal.pone.0259148","journal-title":"PLoS ONE"},{"key":"7609_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","volume":"4","author":"FW Verheugt","year":"2011","unstructured":"Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:191\u20137. https:\/\/doi.org\/10.1016\/j.jcin.2010.10.011","journal-title":"JACC Cardiovasc Interv"},{"key":"7609_CR21","doi-asserted-by":"publisher","first-page":"e001645","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","volume":"8","author":"CS Kwok","year":"2015","unstructured":"Kwok CS, Khan MA, Rao SV, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015;8:e001645. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.001645","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"7609_CR22","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ccd.28800","volume":"96","author":"B Kheiri","year":"2020","unstructured":"Kheiri B, Rao SV, Osman M, et al. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. Catheter Cardiovasc Interv. 2020;96(6):1240\u20138. https:\/\/doi.org\/10.1002\/ccd.28800","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9","key":"7609_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00392-018-1251-1","volume":"107","author":"TG N\u00fchrenberg","year":"2018","unstructured":"N\u00fchrenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. 2018;107(9):807\u201315. https:\/\/doi.org\/10.1007\/s00392-018-1251-1","journal-title":"Clin Res Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07609-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:03:49Z","timestamp":1762880629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7609"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07609-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"12 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}